The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment


Marcellin P., Bonino F., Lau G. K. K. , Farci P., Yurdaydin C., Piratvisuth T., ...More

41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Austria, 26 - 30 April 2006, vol.44 identifier